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at incorrect doses (e.g. under dosing) and/or for a long duration.
Consequently, multiple targeted AMS strategies have evolved and
have been shown to improve antibiotic utilization and favourably
impact on hospital ecology including bacteriological and clinical
outcome.
http://dx.doi.org/10.1016/j.ijid.2014.03.433
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Role of antimicrobial stewardship (AMS) &
strategies for appropriate antimicrobial therapy
E.J. Goldstein
RM Alden Research Laboratory, Santa Monica, CA,
USA
Antimicrobial Stewardship (AMS) is a new “buzz word” that has
resonated across the world because of the pandemic of antimi-
crobial resistance but is in essence a rehashing of the classical
teachings that have always been part of every ID fellowship and
medical residency. Its mantra is selecting the most efﬁcacious,
narrowest spectrum and cost effective therapy to treat the most
likely pathogens at the site of infection. It is essentially a TEAM
effort utilizing multiple elements including formulary restriction,
preauthorization and concurrent or post-therapy review and feed-
back. Supplemental strategies include education, de-escalation,
streamlining, dose optimization, iv to po conversion and automatic
stop dates. Successful programs also need microbiology and cul-
ture stewardship, environmental services and infection prevention
elements. Despite these efforts the C-Suite must often be edu-
cated and convinced that AMS is a Quality measure related to
patient outcomes and not just a budgetary line. Targeting abused
and unnecessary antibiotics and overly broad or ineffective ther-
apies coupled with attention to emergence of bacterial resistance
are key elements of AMS. Problem organisms include resistant P.
aeruginosa, ESBL E. coli, Carbapenemase-resistant Enterobacteri-
aceae and Acinetobacter spp. With the emergence of ESBL E. coli ST
131 H30Rx whose global clonal expansion and its disproportionate
association with sepsis has engendered the use of carbapenems
as the treatment of choice in geographic areas of high preva-
lence and speciﬁc diseases as pyelonephritis and bacteremia. The
emergence of multi-resistant P. aeruginosa has been related to
the selective pressures of overuse of expanded cephalosporins,
piperacillin-tazobactam, ﬂuoroquinolones and class II carbapen-
ems. CREs, which are often clonal, have emerged with the majority
of reported cases selected by non-carbapenem antibiotics and
require intense augmented Infection Control preventions to stop
spread. Appropriate AMS therapy is a quality measure to improve
morbidity and mortality that also can reduce length of stay with
collateral ﬁnancial beneﬁt aswell as improving the resistance rates.
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Pseudomonas resistance in hospital setting;
why pseudomonas sparing is an important AMS
strategy
Y. Carmeli
Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Pseudomonas aeroginosa is an opportunistic pathogen affect-
ing patients with reduced immunity either due to treatment or
disease. It is associated primarily with device related infections
such as ventilator associatedpneumonia and catheter related blood
stream infections. Indeed, P. aeruginosa is an important nosocomial
pathogen and among the leading causes of ventilator associated
pneumonia, bacteremia, and surgical site infections. P. aeroginosa
is hard to treat. It is intrinsically resistant to most antibiotic agents,
and to the handful anti-pseudomonas agents it is acquiring resis-
tance rapidly under antibiotic pressure. Therefore, to preserve
treatment options against P. aeruginosa, it is important to reduce
anti-pseudomonal antibiotic pressure. Antibiotic stewardship pro-
grams aim is to improve the adequacy of antibiotic pressure and
to balance between the need for early effective therapy to treat
an infection with the need to reduce antibiotic pressure in order to
reduce side effects, toxicity and adverse outcomes in the individual
patient as well as to preserve antibiotic for future use. Selection of
antibiotics should be targeted to the pathogens that likely affect the
speciﬁc patient. This decision is complex; it requires understanding
the patient background and condition, the severity of diseases, and
the local microbiology and epidemiology. Nevertheless this is the
most important decision in antibiotic prescribing, and has partic-
ular importance when considering anti-pseudomonal treatment.
Antibiotic stewardship programs should provide advice and tools
that will facilitate stratiﬁcation of patients into risks categories of
infection with P. aeruginosa, with other resistant gram-negative
bacteria, and the risk in delay of appropriate therapy. This risk
stratiﬁcation should be based on various exposures including to
the healthcare setting and to antibiotics, the patient medical his-
tory and the local epidemiology. Successful antibiotic stewardship
will improve patient outcomes and will reduce antibiotic pressure.
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